New ALS study suggests targeting VCP could protect nerve cells
Overactivity of a molecular system that normally helps clear unwanted proteins may contribute to nerve cell damage in certain genetic…
Articles by Marisa Wexler, MS
Clene, FDA to discuss survival data and approval path for CNM-Au8
Clene is scheduled to meet with the U.S. Food and Drug Administration (FDA) in the coming months to discuss…
ALS Association fears ‘instability’ with removal of NINDS director
The ALS Association is urging members of Congress to take action to address issues with instability in leadership at…
Genetic activity in blood could help detect ALS, predict survival: Study
Researchers have developed a novel approach to detect amyotrophic lateral sclerosis (ALS) and predict survival outcomes in patients by…
ALS medication AMX0114 shows safety, moves to 2nd trial group
AMX0114, being developed as an amyotrophic lateral sclerosis (ALS) medication, has been well tolerated in early clinical testing, and…
Neurosense to seek PrimeC approval in Canada next year
Neurosense Therapeutics is gearing up to submit an application to Health Canada for approval of PrimeC to treat…
Survival benefit seen for patients with ALS drug CNM-Au8: New data
Clene is planning to submit an application to the U.S. Food and Drug Administration (FDA) in early 2026 requesting accelerated…
New legislation to study why US veterans face increased ALS risk
A bipartisan team of congressional representatives is pushing for new legislation that aims to understand why veterans are at increased…
ALS oral therapy slows disease progression in preclinical testing
M102, an experimental oral therapy designed to simultaneously activate two molecular pathways that protect against nerve cell damage, showed promise…
Experimental drug K9 for ALS joins Healey & AMG Center trial program
Inflammasome Therapeutics is teaming up with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital…